Literature DB >> 33946367

Vaccination with Prion Peptide-Displaying Polyomavirus-Like Particles Prolongs Incubation Time in Scrapie-Infected Mice.

Martin Eiden1, Alma Gedvilaite2, Fabienne Leidel1,3, Rainer G Ulrich1, Martin H Groschup1.   

Abstract

Prion diseases like scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle or Creutzfeldt-Jakob disease (CJD) in humans are fatal neurodegenerative diseases characterized by the conformational conversion of the normal, mainly α-helical cellular prion protein (PrPC) into the abnormal β-sheet rich infectious isoform PrPSc. Various therapeutic or prophylactic approaches have been conducted, but no approved therapeutic treatment is available so far. Immunisation against prions is hampered by the self-tolerance to PrPC in mammalian species. One strategy to avoid this tolerance is presenting PrP variants in virus-like particles (VLPs). Therefore, we vaccinated C57/BL6 mice with nine prion peptide variants presented by hamster polyomavirus capsid protein VP1/VP2-derived VLPs. Mice were subsequently challenged intraperitoneally with the murine RML prion strain. Importantly, one group exhibited significantly increased mean survival time of 240 days post-inoculation compared with 202 days of the control group. These data show that immunisation with VLPs presenting PrP peptides may represent a promising strategy for an effective vaccination against transmissible spongiform encephalitis agents.

Entities:  

Keywords:  active immunisation; polyomavirus; prion disease; virus-like particles

Year:  2021        PMID: 33946367     DOI: 10.3390/v13050811

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  57 in total

1.  Antibodies inhibit prion propagation and clear cell cultures of prion infectivity.

Authors:  D Peretz; R A Williamson; K Kaneko; J Vergara; E Leclerc; G Schmitt-Ulms; I R Mehlhorn; G Legname; M R Wormald; P M Rudd; R A Dwek; D R Burton; S B Prusiner
Journal:  Nature       Date:  2001-08-16       Impact factor: 49.962

2.  Prions Strongly Reduce NMDA Receptor S-Nitrosylation Levels at Pre-symptomatic and Terminal Stages of Prion Diseases.

Authors:  Elisa Meneghetti; Lisa Gasperini; Tommaso Virgilio; Fabio Moda; Fabrizio Tagliavini; Federico Benetti; Giuseppe Legname
Journal:  Mol Neurobiol       Date:  2019-02-01       Impact factor: 5.590

3.  Characterization of prion protein function by focal neurite stimulation.

Authors:  Ladan Amin; Xuan T A Nguyen; Irene Giulia Rolle; Elisa D'Este; Gabriele Giachin; Thanh Hoa Tran; Vladka Čurin Šerbec; Dan Cojoc; Giuseppe Legname
Journal:  J Cell Sci       Date:  2016-09-02       Impact factor: 5.285

4.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease.

Authors:  Anthony R White; Perry Enever; Mourad Tayebi; Rosey Mushens; Jackie Linehan; Sebastian Brandner; David Anstee; John Collinge; Simon Hawke
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

5.  Sympathetic innervation of lymphoreticular organs is rate limiting for prion neuroinvasion.

Authors:  M Glatzel; F L Heppner; K M Albers; A Aguzzi
Journal:  Neuron       Date:  2001-07-19       Impact factor: 17.173

6.  Differences in proteinase K resistance and neuronal deposition of abnormal prion proteins characterize bovine spongiform encephalopathy (BSE) and scrapie strains.

Authors:  T Kuczius; M H Groschup
Journal:  Mol Med       Date:  1999-06       Impact factor: 6.354

7.  Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo.

Authors:  Martin J Sadowski; Joanna Pankiewicz; Frances Prelli; Henrieta Scholtzova; Daryl S Spinner; Regina B Kascsak; Richard J Kascsak; Thomas Wisniewski
Journal:  Neurobiol Dis       Date:  2009-05       Impact factor: 5.996

8.  Discovery and Preliminary SAR of Arylpiperazines as Novel, Brainpenetrant Antiprion Compounds.

Authors:  Zhe Li; Joel Gever; Satish Rao; Kartika Widjaja; Stanley B Prusiner; B Michael Silber
Journal:  ACS Med Chem Lett       Date:  2013-04-11       Impact factor: 4.345

9.  Induction of insert-specific immune response in mice by hamster polyomavirus VP1 derived virus-like particles carrying LCMV GP33 CTL epitope.

Authors:  Egle Mazeike; Alma Gedvilaite; Ulrike Blohm
Journal:  Virus Res       Date:  2011-08-16       Impact factor: 3.303

Review 10.  Immunotherapy against Prion Disease.

Authors:  Yue Ma; Jiyan Ma
Journal:  Pathogens       Date:  2020-03-14
View more
  1 in total

Review 1.  Hamster Polyomavirus Research: Past, Present, and Future.

Authors:  Burkhard Jandrig; Hans Krause; Wolfgang Zimmermann; Emilija Vasiliunaite; Alma Gedvilaite; Rainer G Ulrich
Journal:  Viruses       Date:  2021-05-13       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.